Aegis Maintains BioLineRx (BLRX) at Buy; Plenty of Opportunity Left in Growing IBD Market
Tweet Send to a Friend
Aegis Capital maintains a Buy rating and $7 price target on BioLineRx, Ltd. (Nasdaq: BLRX) following issuance of new BL-7040 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
